1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 26
2.2 Major Growth Drivers 30
2.3 Market Restraints and Challenges 34
2.4 Emerging Opportunities and Market Trends 37
2.5 Porter?s Fiver Forces Analysis 41
3 Segmentation of Europe Market by Source 45
3.1 Market Overview by Source 45
3.2 Synthetic API 47
3.2.1 Branded Synthetic API 48
3.2.2 Generic Synthetic API 49
3.3 Semi-synthetic API 50
3.4 Natural Origin 51
4 Segmentation of Europe Market by Product Type 52
4.1 Market Overview by Product Type 52
4.2 Standard API 54
4.3 High Potency API (HPAPI) 55
4.3.1 Branded HPAPI 56
4.3.2 Generic HPAPI 57
5 Segmentation of Europe Market by Therapeutic Area 58
5.1 Market Overview by Therapeutic Area 58
5.2 Infectious Diseases 60
5.3 Oncology 61
5.4 Ophthalmology 62
5.5 Cardiovascular Disorders 63
5.6 Central Nervous System 64
5.7 Respiratory Disorders 65
5.8 Metabolic Diseases 66
5.9 Other Therapeutic Areas 67
6 Segmentation of Europe Market by Application 68
6.1 Market Overview by Application 68
6.2 Clinical Use 70
6.3 Commercial Use 71
7 Segmentation of Europe Market by Manufacturer Type 72
7.1 Market Overview by Manufacturer Type 72
7.2 Pharmaceutical Companies 74
7.3 CMOs 76
8 European Market 2022-2032 by Country 78
8.1 Overview of European Market 78
8.2 Germany 81
8.3 U.K. 83
8.4 France 85
8.5 Spain 87
8.6 Italy 89
8.7 Russia 91
8.8 Rest of European Market 93
9 Competitive Landscape 95
9.1 Overview of Key Vendors 95
9.2 New Product Launch, Partnership, Investment, and M&A 98
9.3 Company Profiles 99
Aurobindo Pharma Ltd. 99
Cambrex Corporation 101
Catalent Inc. 102
Dr. Reddy's Laboratories 105
GlaxoSmithKline plc 108
Lonza Group 112
Merck & Co., Inc. 115
Mylan N.V. 117
Novartis AG 119
Pfizer Inc. 121
Sun Pharmaceutical Industries Ltd. 125
Teva Pharmaceutical Industries Ltd. 128
Wuxi AppTec Co., Ltd. 130
RELATED REPORTS 132